About Us

 On March 9, 2010, the significant asset reorganization of the Pharmaceutical Business Divisions between Shanghai Industrial Investment (Holdings) Co., Ltd and Shanghai Pharmaceutical Group was perfectly accomplished and Shanghai Pharmaceuticals Holding Co., Ltd. (hereinafter as "Shanghai Pharma") has officially resumed trading (Stock Code: 601607.SH) since then.

 On March 25, 2010, Shanghai Pharma and Fujian Overseas Chinese Industrial Group signed the framework agreement on overall strategic partnership, which accomplished the overall layout of the distribution networks in Shanghai and other six provinces in East China.

 On April 12, 2010, Shanghai Pharma and Guangzhou Zhongda Holding Co., Ltd. held an agreement-signing ceremony for the recontruction of Guangzhou Z. S. Y. Pharmaceutical Co., Ltd. Hence the Company successfully made the access to the distribution network of South China area.

 On February 23, 2011, Shanghai Pharma and Shanghai Fudan - Zhangjiang Bio-Pharmaceutical Co., Ltd. signed the strategic partnership agreement on R&D of significant and innovative drugs and in the upcoming 6 years, a total of RMB 180 million yuan would be invested to work together with Fudan - Zhangjiang on the comprehensive R&D and industrialization of four types of pharmaceutical products.

 On March 15, 2011, Shanghai Pharma entered an agreement with Taizhou Pharmaceutical Co., Ltd., thus further help to consolidatethe Company’s position in the distribution market.

 On April 7, 2011, Shanghai Pharma got the official approval of the National Development and Reform Commission to acquire 100% shares of China Health System Ltd., Hence the Company successfully made the access to the North China distribution market.

 On April 12, 2011, Shanghai Pharma began to enter into the extensive strategic cooperation with 69 multi-national pharmaceutical companies in such three major business areas as the high-end drugs, high-quality consumption materials and vaccines.

 On May 20, 2011, Shanghai Pharma got listed on the main board of The Stock Exchange of Hong Kong Limited (Stock Code: 02607.HK). After exercising the overallotment option of H shares, Shanghai Pharma issued a total of 2,688,910,538 shares in both Shanghai and Hong Kong market. The cornerstone investors include Pfizer, Temasek, Guoco and Bank of China.

 On August 9, 2011, Shanghai Pharma signed a cooperation agreement with Dong-A Pharmaceutical Co., Ltd. under which agreement the extensive cooperation programs shall be carried out in terms of pharmaceutical R&D, registrations and marketing.

 On August 18, 2011, Shanghai Pharma made an investment of RMB 344 million yuan in the establishment of Shanghai Pharma Shanhe Wuxi Pharmaceutical Co., Ltd. in collaboration with Jiangsu Wuxi Shanhe Group in an effort to consolidate and promote the Company's competitiveness in Jiangsu area.

 In September 2011, Shanghai Pharma accomplished the acquisition of 96.9% shares of Xinya and 100% shares of Shanghai Huakang Pharmaceutical Co., Ltd., indicating the completion of anti-biotic business reconstruction being included in the listed company.

 In January 2012, Shanghai Pharma signed an agreement with Shanghai Jinhe Bio-Technology Co., Ltd., to acquire 51% of its total shares, and to enlarge the investment in the area of oncology API.

 In February 2012, Shanghai Pharma acquired 70% shares of Changzhou Kony Pharmaceutical Co., Ltd., with the remaining 30% shares to be acquired in the following 2 years, so as to enrich the product lines in the areas of both the anti-virus and cardiovascular, and to enlarge the investment in featured API.

 On September 4, 2012, the foundation was laid for the Phase I project of the high value added active pharmaceutical ingredients production base of Shanghai Pharma in Spark Zone, with which the Company made a new step forward in the development of the areas of the featured and high-end active pharmaceutical ingredients.

 On September 27, 2012, Shanghai Pharma completed the acquisition of Nantong Zhongbao Pharmaceuticals Co., Ltd. and set up Shanghai Zhonghua Pharmaceutical Nantong Co., Ltd. in attainment of resource integration and strengthening the market competitiveness of cooling serial products.

 On October 11, 2012, the foundation was officially laid for an expansion project the liquid formulation production base of Shanghai SINE Pharmaceutical Plant Co. Ltd., an affiliate of Shanghai Pharma, in Jinshan, which indicates that Shanghai Pharma has begun to implement the strategic plans to become a big and powerful liquid preparation manufacturer and to realize the industrial concentration.

 On March 16, 2013, the foundation was laid for the overall resettlement and expansion project of Hangzhou Huqingyutang Pharmaceutical Co., Ltd., an affiliate of Shanghai Pharma. Hence Huqingyutang Pharmaceutical began to enter into a new stage of business development.

 On April 18, 2013, the opening ceremony was launched for Nantong Changyou Pharmaceutical Science and Technology Co., Ltd., which is an active pharmaceutical ingredients production base of Changzhou Pharmaceutical Incorporated, an affiliate of Shanghai Pharma. Hence Shanghai Pharma made a significant step forward in the development of the hige value added active pharmaceutical ingredients.

 On June 20, 2013, Shanghai Pharma acquired Dongying (Jiangsu) Pharmaceuticals Co., Ltd. to fill up the gap in the area of both anesthetics and muscle relaxants, enrich the product lines in the cardio-cerebral-vascular, and build up a high-end generic company with core competitiveness in the domestic market.

 On July 31, 2013, Shanghai Pharma and the Second Military Medical University signed a framework cooperation agreement on the Translational Medicine Alliance between the Second Military Medical University and Shanghai Pharma, under which both parties shall strengthen in-depth integration of production, education, research and medicine, improve R&D efficiency and accelerate the industrialization of scientific research achievements.

 In December 2013, Shanghai Pharma acquired Shanghai Jiaolian Pharmaceutical R&D Co., Ltd., which will help improve the Company’s biopharmaceutical R&D capability and attain a leading position in the area of antibody drugs, which are noted for higher gross profit and higher output value, in the future.

 On March 25, 2014, Shanghai Pharma opened its official Weibo account, marking the Company’s presence on new media.

 In April 2014, the Institute of Chinese Medicine of Shanghai Pharma Central Research Institute and “Shanghai Chinese Medicine Research Institute” got officially established, which indicates another new step forward by the Company in terms of the secondary R&D of Chinese medicine and the R&D of innovative preparations.

 On April 9, 2014, Shanghai Pharmaceutical Medicine Sales Co., Ltd. was officially established, which indicates that Shanghai Pharma Centerl Marketing has officially entered into practical operation. On April 29, Shanghai Pharmaceutical Medicine Sales Co., Ltd. and Carefree Pharmaceutical Co., Ltd. signed a cooperation agreement, under which Shanghai Shangke Pharmaceuticals Co., Ltd. was established, so as to uplift Shanghai Pharma’s marketing capability and boost the sales of industrial products.

 In May 2014, the “Recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment injection", jointly developed by Shanghai Pharma and Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd. obtained the clinical trial approval issued by the China Food and Drug Administration and thereby officially entered the clinical trial stage; the investigational new drug application of the "Recombinant humanized anti-CD20 monoclonal antibody injection" project, which was introduced and developed by Shanghai Pharma, was accepted by the China Food and Drug Administration.

 In June 2014, Shanghai Pharmaceuticals Holding Co., Ltd established Sichuan Greentech Co., Ltd jointly with Sichuan Green Angel Equity Investment Fund and Sichuan Kelun Pharmaceutical Co., Ltd. etc., so as to strengthen cooperation in innovative drug R&D.

 On June 13, 2014, the BOD Executive Committee of Shanghai Pharma deliberated and passed the Proposal on acquisition by SPH Keyuan Xinhai Pharmaceutical Co., Ltd. of the Shares of Beijing Xinhai Fengyuan Bio-Pharm Science & Technology Development Co., Ltd., Shanxi Huaxin Pharmaceutical Co., Ltd. and Ordos Elion Medicine Co., Ltd. for further expansion of the drug distribution network in North China and enhancement of the market competitiveness.

 In June 2014, Shanghai Pharmaceutical Co., Ltd., which is affiliated to Shanghai Pharma, acquired 75% shares of Shandong Shanghai Pharma Pharmaceuticals Co., Ltd., a company incorporated by Shandong Hongjitang Medicine Group Co., Ltd. through splitting other business irrelevant to pharmaceutical distribution, for RMB 407 million yuan. Furthermore, Shanghai Pharma increased 35% shares of the holdings of Shandong Shanghai Pharma Shanglian Pharmaceutical Co., Ltd. for RMB 30.45 million yuan to further expand the distribution network in Shandong area.

 The construction of Jinqiao base expansion project of SINE Pharmaceutical Co., Ltd. which is affiliated to Shanghai Pharma, started on June 30, 2014. As a core manufacturing base of high-end pharmaceutical products, Jinqiao base marks another milestone for SINE to launch a new round of “1+2” development strategy.

 On December 26, 2014, Shanghai Industrial Pharmaceutical R&D Co., Ltd., a subsidiary of Shanghai Pharma, signed a cooperation agreement with Guangdong Sunnico Medical Technology Co., Ltd., a subsidiary of Xingquan Global, under which Shanghai Industrial Pharmaceutical R&D Co., Ltd. made an additional contribution of RMB 229.5 million in cash to Xingquan Global in exchange for a 51% stake. Shanghai Pharma has thereby further expanded its medical device business with an effort to seek transformation into a medical service provider and to create its core competitiveness in the medical device business sector.

 On January 9, 2015, the project “Innovative Research and Industrialization of the Core Technology System for the Secondary Development of Traditional Chinese Medicine”, which was accomplished by Chiatai Qingchunbao Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharma, in collaboration with other universities, research institutions and companies, won the first prized of the National Science and Technology Progress Award 2014. It is the only innovation result in the pharmaceutical industry that won the first prized of the National Science and Technology Progress Award of the year. Hence Shanghai Pharma became the first monomer pharmaceutical company that has won the first prized of the National Science and Technology Progress Award in China.

 On February 25, 2015, Shanghai Huayu Chinese Herbs Co., Ltd. and Shanghai Jinhe Bio-Tech Co., Ltd., both subsidiaries of Shanghai Pharma, reorganized Dali Zhonggu Yew Biological Co., Ltd. (hereinafter referred to as “Zhonggu Biological”) by way of investment in cash, enabling Shanghai Pharma to take the control of Zhonggu Biological. This move indicates that Shanghai Pharma will further integrate its oncology drug industry chain, build its advantage in APIs, develop GAP planting base of Chinese medicinal materials and build a grand health industry chain.

 On March 9, 2015, Shanghai Pharma and the e-commerce management team set up SPH Macro-Health Cloud Business Co., Ltd. with investment in cash. The new company positions itself as a trade-oriented e-commerce enterprise to provide O2O sales of prescription drugs and health management services to patients.

On March 16, 2015, Shanghai Pharma signed a strategic cooperation framework agreement with the People’s Government of Dali Prefecture, Yunnan Province, indicating that Shanghai Pharma and Dali Prefecture will further carry out comprehensive exchange and cooperation programs at multiple levels, through multiple channels and in multiple areas.

Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharma, began the construction of the Spark Production Base on April 26, 2015 in an effort to develop featured APIs and high-end APIs and realize the integration of APIs and preparations.

On May 15, 2015, Shanghai Pharma and JD.COM signed a strategic cooperation framework agreement to establish a comprehensive strategic partnership at three levels including strategy, capital and business.

On May 19, 2015, SPH North Pharmaceutical Co., Ltd. held a groundbreaking ceremony for its R&D and Industrialization Base, which signified important progress made by Shanghai Pharma in its strategic layout in Liaoning and even in North China. Hence Shanghai Pharma North Pharmaceutical’s development system integrating production, education and research has preliminarily taken shape.

On July 1, 2015, SPH Zhonghua Pharmaceutical Co., Ltd. held a groundbreaking ceremony for the overall resettlement project. SPH Zhonghua Pharmaceutical planned to take this as an opportunity to promote the historical glory of this enterprise of China’s time-honored brand and further expand the influence of the renowned national brand of “Dragon & Tiger” in domestic and international markets.

On July 6, 2015, Shanghai Pharma and Wonders Information Co., Ltd. signed a strategic cooperation agreement to carry out comprehensive and in-depth strategic cooperation in the areas of pharmaceutical informationization and Internet + Pharmaceutical.

On August 18, 2015, SPH Cloud Health completed the first round of financing from Shanghai Pharma, JD.COM and IDG Capital Partners etc., with a total of RMB 1.112 billion raised. Hence the capital strength has got dramatically improved.

On September 30, 2015, Shanghai Pharma and WWW.DXY.CN signed a cooperation agreement to establish a comprehensive strategic partnership in the areas of pharmaceutical e-commerce and mobile medical services. According to the agreement, the two sides shall share resources and complement each other’s advantages, so as to explore and develop the market and business opportunities in the area of mobile medical services together.

On October 21, 2015, Shanghai Pharma set up the “Shanghai Pharma Caring Guardian Program” special fund in collaboration with China Youth Development Foundation. The initial RMB 10 million will be used, in three years, to support the construction of village clinics in remote mountain areas, rare disease patients in rural areas, the training of rural doctors, and relevant activities such as “deliver volunteer medical consultation into villages”.

On November 12, 2015, Shanghai Pharma made an additional investment of RMB 15,124.50 in Liaoning Pharmaceutical Foreign Trade Corporation in an effort to expand its pharmaceutical distribution network in Northeast China and to form strong synergy with the Company’s existing platform in North China.

On January 8, 2016, Shanghai Pharma signed the Limited Partnership Agreement on the Establishment of Shanghai Healthcare Industry Equity Investment Fund Partnership Enterprise (Limited Partnership). According to the agreement, Shanghai Pharma shall make an investment of RMB 250 million to establish Shanghai Healthcare Industry Equity Investment Fund Partnership Enterprise, which is a significant step taken by Shanghai Pharma to seek innovations in investment and R&D.

On January 8, 2016, the “R&D and Industrialization of Artificial Musk” Project completed by Shanghai Traditional Chinese Medicine Co., Ltd., a wholly-owned subsidiary of Shanghai Pharma, in collaboration with relevant universities and companies, won the first prize of the National Science and Technology Progress Award 2015 issued by the State Council.

On February 2, 2016, the Project Signing Ceremony of Shanghai SPH–Yisheng Medical Investment and Management Co., Ltd. (hereinafter referred to as “SPH–Yisheng”), a joint venture set up by Shanghai Pharma and Shanghai Yisheng Medical Investment and Management Co., Ltd., was held. The Company will take SPH–Yisheng as an investment platform to carry out the investment, M&A and operational management of hemodialysis services for kidney disease patients.

On March 18, 2016, Shanghai Yuepu and Shengtai Investment made an investment of RMB 67.5 million each in Shanghai Pharma Big Health Cloud Commerce Co., Ltd. (hereinafter referred to as “Shanghai Pharma Cloud Health”), an e-commerce platform affiliated to Shanghai Pharma. After the capital increase, the registered capital of Shanghai Pharma Cloud Health increases to RMB 1.3 billion.

On April 19, 2016, the “Ginkgo Biloba Extract Component Analysis” Project completed by Shanghai Xingling Science and Technology Pharmaceutical Co., Ltd.,a subsidiary of Shanghai Pharma, won a Gold Award at Geneva International Exhibition of Inventions, which indicates that the research project has attained international recognition.

In May 2016, the “SPH3127 API and Its Tablets”, a chemical drug of Category 1.1 developed by Northern Pharmaceutical, a wholly-owned subsidiary of Shanghai Pharma, obtained the drug clinical trial approval issued by China Food and Drug Administration.

On May 6, 2016, Shanghai Traditional Chinese Medicine Co., Ltd., a wholly-owned subsidiary of Shanghai Pharma, signed the Joint Venture Contract with TSUMURA & CO., a Japanese pharmaceutical company, under which the two companies will work together to set up a joint venture and carry out the R&D and production of TCM formula granules. That is viewed as an important move by Shanghai Pharma to seek development in the whole industrial chain of the Chinese medicine.

On May 12, 2016, Shanghai Pharma, Guangzhou Baiyunshan Pharmaceutical, Harbin Pharmaceutical, ChinaHealthCare, Tianjin Pharmaceuticals and Chongqing Pharmaceutical signed a Memorandum of Understanding on Building a Joint Pharmaceutical Platform, under which a new model of competition-cooperation shall be triggered by strengthening strategic partnership and demonstrating the collaborative advantages in the industry.

In June 2016, the “Salvianolic Acid A and Its Powder Injection”, a traditional Chinese medicine of Category 1 developed by Chiatai Qingchunbao Pharmaceutical, a wholly-owned subsidiary of Shanghai Pharma, obtained the drug clinical trial approval issued by China Food and Drug Administration.

In September 2016, Shanghai Pharma’s “Recombinant Anti-CD20 Humanized Monoclonal Antibody Injection” obtained the drug clinical trial approval issued by China Food and Drug Administration.

In November 2016, the “Rosuvastatin Calcium Tablets” manufactured by Changzhou Pharmaceutical, a wholly-owned subsidiary of Shanghai Pharma, obtained a drug approval number from U.S. FDA, which will positively promote the company’s endeavor to explore the global preparations market.

On August 3, 2016, Shanghai Pharma’s wholly-owned subsidiary SIIC signed an acquisition agreement on the project of joint privatization of Vitaco Holdings Limited in Australia, under which SIIC plans to acquire a 60% of stake in Vitaco for about RMB 938 million. The deal commenced after approved by the Federal Court of Australia on December 6, 2016.

In December 2016,the “SPH1188-11 Tablets and Its API” developed by Northern Pharmaceutical, a wholly-owned subsidiary of Shanghai Pharma, obtained the drug clinical trial approval issued by China Food and Drug Administration.

 

The subject of concern
Produced By 大汉网络 大汉版通发布系统